Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — European Society of Cardiology (ESC) Congress together with World Congress of Cardiology 2 (August 2025)
15 slides from Novo Nordisk A/s Class B's conference presentation, Aug 31, 2025
Slide 1: Semaglutide is associated with a lower risk of cardiovascular events compared with tirzepatide
Semaglutide is associated with a lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice Results from the STEER study (Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People Wit
Slide 2: Disclosures
Disclosures • All authors are employees and shareholders of Novo Nordisk Inc. Wilson L, et al. Presented at the European Society of Cardiology (ESC) Congress together with World Congress of Cardiology; Madrid, Spain; August 29 - September 1, 2025.
Slide 3: Background
Background Semaglutide injection 2.4 mg Tirzepatide GLP-1 receptor agonist (hereafter referred to as “semaglutide”) GIP and GLP-1 receptor co-agonist • FDA approved in June 2021 for chronic weight • FDA approved in May 2022 for type 2 diabetes management (Wegovy®)1 (Mounjaro®)3 and November 2023 for
Slide 4: STEER Study Design
STEER Study Design US Komodo Research Database Study population • ≥45 years of age • Without diabetes • Overweight/obesity* • Initiated semaglutide or tirzepatide • Established ASCVD† on or after May 13, 2022 Jan 1, 2016 Jan 31, 2025 Index date = treatment initiation End of follow-up‡ The propensity
Slide 5: Eligibility Criteria and Cohort Attrition
Eligibility Criteria and Cohort Attrition Patients with overweight/obesity, n = 149,344,662 Patients with established ASCVD, n = 23,779,686 Patients ≥45 years of age by the end of data availability The eligibility date was defined as latest date of first overweight/obesity ascertainment, first ASCVD
Slide 6: Baseline Demographic Characteristics
Baseline Demographic Characteristics (Post-Matching) Semaglutide Tirzepatide Semaglutide Tirzepatide Characteristic (n = 10,625) (n = 10,625) Difference* Characteristic (n = 10,625) (n = 10,625) Difference* Mean (SD) follow-up time, 8.3 (6.4) 8.6 (7.1) −0.050 Region, n (%) 0.073 months South 4033 (3
Slide 7: Baseline Disease Characteristics
Baseline Disease Characteristics (Post-Matching) Semaglutide Tirzepatide Semaglutide Tirzepatide Characteristic (n = 10,625) (n = 10,625) Difference* Characteristic (n = 10,625) (n = 10,625) Difference* ASCVD eligibility criteria, Concomitant CV medication n (%) use, n (%) Peripheral artery disease
Slide 8: Revised 3-Point MACE (ITT Analysis)
Revised 3-Point MACE* The ITT analysis followed patients through the end of follow-up† regardless of persistence on therapy (ITT Analysis) Events, Incidence rate per Mean (SD) n (%) 1000 patient-years (95% CI) follow-up 8% 2.0% Tirzepatide Tirzepatide 83 (0.8) 10.8 (8.61-13.30) 8.6 (7.1) Cumulative
Slide 9: Revised 5-Point MACE (ITT Analysis)
Revised 5-Point MACE* The ITT analysis followed patients through the end of follow-up† regardless of persistence on therapy (ITT Analysis) Events, Incidence rate per Mean (SD) n (%) 1000 patient-years (95% CI) follow-up 8% 2.0% Tirzepatide Tirzepatide 161 (1.5) 21.0 (17.87-24.39) 8.6 (7.1) Cumulativ
Slide 10: MACE Outcomes (ITT Analysis)
MACE Outcomes (ITT Analysis) Incidence rate per 1000 patient-years Semaglutide Tirzepatide HR (95% CI) P value Revised 5-point MACE* 16.7 21.0 0.78 (0.62-0.99) 0.040 Myocardial infarction 3.8 5.4 0.70 (0.43-1.14) 0.149 Heart failure 4.3 6.1 0.68 (0.44-1.07) 0.097 Stroke 2.4 3.9 0.64 (0.35-1.15) 0.13
Slide 11: Revised 3-Point MACE (Per-Protocol Analysis)
Per-protocol sensitivity analysis censored patients at Revised 3-Point MACE* treatment discontinuation (gap in therapy >30 days) (Per-Protocol Analysis) Events, Incidence rate per Mean (SD) n (%) 1000 patient-years (95% CI) follow-up Tirzepatide 39 (0.4) 10.3 (7.13-13.99) 4.3 (4.2) 8% 2.0% Tirzepati
Slide 12: Revised 5-Point MACE (Per-Protocol Analysis)
Per-protocol sensitivity analysis censored patients at Revised 5-Point MACE* treatment discontinuation (gap in therapy >30 days) (Per-Protocol Analysis) Events, Incidence rate per Mean (SD) n (%) 1000 patient-years (95% CI) follow-up Tirzepatide 80 (0.8) 21.1 (16.63-26.14) 4.3 (4.2) 8% 2.0% Tirzepat
Slide 13: MACE Outcomes (Per-Protocol Analysis)
MACE Outcomes 0 mortality events were reported, resulting in (Per-Protocol Analysis) equivalent traditional MACE (CV-related mortality) and revised MACE (all-cause mortality) outcomes Incidence rate per 1000 patient-years Semaglutide Tirzepatide HR (95% CI) P value Revised 5-point MACE* 12.3 21.1 0.
Slide 14: Strengths and Limitations
Strengths and Limitations Strengths Limitations Cohorts were well balanced across a Administrative claims data may be large number of comorbid conditions subject to coding inaccuracies and concomitant medications Potential for unmeasured Large sample size, with confounding ~10,000 patients per treat
Slide 15: Conclusions
Conclusions Significantly lower risk of revised 3-point MACE with From the STEER Real-World Study semaglutide vs tirzepatide In this real-world study of US patients with overweight or obesity and ASCVD but without 29% diabetes, the primary endpoint demonstrated a lower risk of CV events with semaglu